Chronic impairment of cardiac function can be an important health risk and impair the quality of life, and may even be life-threatening for long-term survivors of allogeneic hematopoietic cell transplantation (HCT). However, risk factors for and/or the underlying mechanism of cardiac dysfunction in the chronic phase of HCT are still not fully understood. We retrospectively investigated factors affecting cardiac function and left-ventricular hypertrophy (LVH) in the chronic phase of HCT. Sixty-three recipients who survived for 41 year after receiving HCT were evaluated using echocardiography. Based on simple linear regression models, high-dose TBI-based conditioning was significantly associated with a decrease in left-ventricular ejection fraction and the early peak flow velocity/atrial peak flow velocity ratio, following HCT (coefficient ¼ À 5.550, P ¼ 0.02 and coefficient ¼ À 0.268, P ¼ 0.02, respectively). These associations remained significant with the use of multiple linear regression models. Additionally, the serum ferritin (s-ferritin) level before HCT was found to be a significant risk factor for LVH on multivariable logistic analysis (P ¼ 0.03). In conclusion, our study demonstrated that a myeloablative regimen, especially one that involved high-dose TBI, impaired cardiac function, and that a high s-ferritin level might be associated with the development of LVH in the chronic phase of HCT.
INTRODUCTION
The long-term survival rate after allogeneic hematopoietic cell transplantation (HCT) has significantly improved over recent decades because of improvements in the HCT procedure. However, chronic complications, such as cardiovascular disease, have become increasingly evident and constitute a serious problem in long-term survivors of HCT. [1] [2] [3] It is well known that the high-dose CY used for conditioning is a major cause of acute cardiotoxicity after HCT. 4, 5 However, it is still unclear as to which factors contribute to chronic cardiotoxicity after HCT. It is possible that conditioning regimens consisting of highdose CY or high-dose TBI influence cardiac function even in the chronic phase, 6, 7 a contention that has not been evaluated in adult patients. Cytokines, such as IL-2 and TNF-alpha, have the potential to affect myocardial tissue adversely, 8 while TNF-alpha is also thought to be involved in the pathogenesis of chronic GVHD. 9 Chronic GVHD may therefore contribute to cardiac tissue damage via cytokines. However, it has not yet been determined whether chronic GVHD has a detrimental effect on cardiac function after HCT.
Left-ventricular hypertrophy (LVH) is often seen in patients with hypertension (HT). One report indicates that inflammatory cytokines, including IL-2 and TNF-alpha, have a role in the development of LVH. 10 It is still not clear which factors affect LVH in HCT recipients. Here we comprehensively evaluate the factors that affect chronic LVH and cardiac systolic and diastolic function after HCT, in a retrospective cohort study that used echocardiographic assessment.
MATERIALS AND METHODS

Study design
We examined left-ventricular systolic and diastolic function and LVH in patients who were eligible for the study as they had received HCT between April 2000 and June 2010 at our institution, had undergone an echocardiographic examination within the 2 months before HCT and had survived for 41 year after HCT. All the evaluated patients visited our hospital regularly. Patients who received more than two allogeneic HCT were excluded from analysis. We also statistically investigated the factors that influenced cardiac function after HCT. Written informed consent was obtained from all the enrolled patients and this study protocol was approved by the Institutional Review Board of our institution.
Cardiac evaluation
Echocardiographic examinations were performed using a Power Vision 6000 (Toshiba, Tokyo, Japan). An electrocardiographic tracing was recorded in the left-lateral decubitus position simultaneously with the echocardiogram. Transducer frequency was 2.5 or 3.5 MHz. We recorded left-ventricular end-diastolic dimension and left-ventricular end-systolic dimension from the left-parasternal long axis view at the high papillary muscle level and calculated left-ventricular ejection fraction (LVEF) by the Teichholtz method. Trans-mitral flow-velocity patterns were measured on an apical, four-chamber view according to the standard method. We assessed LVEF as a surrogate marker of LV systolic function and the early 1 peak flow velocity/atrial peak flow velocity (E/A ratio) as a surrogate marker of LV diastolic function. 'LVH after HCT' was identified when the interventricular septal wall and/or the posterior wall became 412-mm thick after HCT.
Statistical analysis
We assessed the possible factors that influence cardiac function after HCT, including intensity of the conditioning regimen (high-dose, TBI-based conditioning regimens vs high-dose busulfan (BU)-based conditioning regimens vs all others), sex, age, a history of HT, hemoglobin concentration, serum ferritin (s-ferritin) levels, chronic GVHD and cumulative dose of anthracyclines. All the high-dose TBI-based conditioning regimens included TBI 1200 cGy and CY 120 mg/kg. High-dose BU-based conditioning regimens used oral BU 16 mg or i.v. BU 12.8 mg and CY 120 mg/kg; all other regimens were defined as reduced intensity conditioning (RIC). HT was defined as a history of HT within 1 year after HCT. We also analyzed data on hemoglobin concentration determined 1 year after HCT, and s-ferritin levels taken before HCT. We defined a history of chronic GVHD as the presence of chronic GVHD within 1 year of HCT. We calculated the relative cumulative dose of anthracyclines with the use of a multiplier of 1 for doxorubicin, 0.5 for DNR, 1.6 for idarubicin, 3.4 for mitoxantrone and 0.1 for aclarubicin.
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All statistical tests were interpreted at the 5% significance level. All P-values and 95% confidence intervals were two-sided. Simple or multiple linear regression analysis was used to assess the associations of the pre-transplant or the post-transplant variables with the differences in LVEF or E/A measured before HCT and at the follow-up visit. To assess whether the correlation between the type of pre-transplant conditioning regimen and measures, including change in LVEF or E/A, varied significantly with covariates that included age, sex or chronic GVHD, first-order interactions between the variable and the covariates were inserted into a regression model that contained the interaction term and both covariates as main effects. Analysis of residuals was performed to examine model fit and adherence to regression assumptions. Multi-colinearity was assessed using a variance inflation factor. A variance inflation factor exceeding 10 is thought to indicate serious multi-colinearity, and values 44.0 may be a cause for concern. 12 Changes in LVEF or E/A before and after HCT were tested for significance with a paired t-test. Repeated measures analysis of variance was used to assess the differences in the degree of change in LVEF or E/A before and after HCT among the groups divided by the type of pre-transplant conditioning regimen. Univariable or multivariable logistic regression analysis was used to estimate the odds ratio for incidence of LVH. Nonlinear effects of continuous independent variables were evaluated using quadratic and log transformations. The presence of effect modification was tested by the insertion of first-order interaction terms into appropriate regression models. We calculated the 95% confidence interval for each odds ratio. All statistical analyses were performed using PASW Statistics 17.0 (SPSS, Chicago, IL, USA).
RESULTS
Study cohort
One hundred and twenty-three patients underwent allogeneic HCT at our institution between April 2000 and June 2010. In all, 25 patients died and 20 patients had moved to another hospital, leaving 78 outpatients at our institution. Of these, seven were missing pre-HCT echocardiographic data and five patients had received more than two allogeneic HCT. Sixty-six patients thus met the study criteria. However, consent for the study could not be obtained from three patients. Ultimately, a total of 63 patients were eligible for participation in the study; of these 63 patients, 56 without LVH at baseline were eligible for analysis of the incidence of LVH.
Patient characteristics
Characteristics of study subjects at baseline are shown in Table 1 . The diagnoses in the 63 patients included de novo AML in 22 patients, ALL in 16 patients, myelodysplastic syndrome (MDS)/AML in nine patients, non-Hodgkin's lymphoma in five patients, CML in three patients, adult T-cell leukemia in three patients, aplastic anemia in three patients and one each of biphenotypic acute leukemia and chronic active EB virus infection. In most of the patients, CsA was used for prophylaxis against GVHD. Just one patient received mediastinal radiation therapy prior to HCT. Table 2 . The LVEF and E/A before HCT in the two myeloablative conditioning groups were higher than those in cases who underwent RIC. In the interval from pre-to post-HCT, the LVEF decreased significantly in the high-dose, TBI-based conditioning group as did the E/A with both high-dose TBI-based and high-dose BU-based conditioning ( Table 2, Figures 1a and b) . In the simple linear regression analysis that assessed the relationship between LVEF or E/A and other factors, high-dose TBI-based conditioning was significantly associated with a decrease in LVEF (Table 3 ).
Furthermore, we tested several regression models to assess the relationship between LVEF or E/A and the conditioning regimen, using multiple linear regression analyses (Table 4 ). The high-dose, TBI-based conditioning regimen was significantly associated with P r e -t r a n s p l a n t P o s t -t r a n s p l a n t P r e -t r a n s p l a n t P o s t -t r a n s p l a n t (%) Figure 1 . (a) Changes in LVEF from pre-transplant to post-transplant. *P ¼ 0.001; w, z: not statistically significant; and y: there were statistically significant differences among the three groups (P ¼ 0.005). (b) Changes of E/A from pre-transplant to post-transplant. *Po0.001; w P ¼ 0.004; z: not statistically significant; and y: there were statistically significant differences among the three groups (P ¼ 0.02). Cardiac dysfunction in the chronic phase of HCT M Nishimoto et al a decrease in LVEF and E/A after HCT, and the high-dose BU-based conditioning regimen showed a significant decrease in E/A after HCT, following adjustment for chronic GVHD, s-ferritin, cumulative dose of anthracyclines and a history of HT (Table 4 ). In addition, after adjustment for sex, age and hemoglobin concentration, the high-dose TBI-based conditioning regimen was significantly associated with a decrease in LVEF and E/A after HCT, and the high-dose BU-based conditioning regimen showed a significant decrease in E/A after HCT (Supplementary Table 1) . Twelve patients received a new diagnosis of LVH after HCT. Several logistic regression models were tested to assess the effects of the pre-and the post-transplant variables on the incidence of LVH (Table 5) . With logistic regression analysis, insertion of a quadratic transformation of s-ferritin alone improved the fit compared with the linear model. Because both the linear and the quadratic transformation of s-ferritin were significant in all models at Po0.05, both of these variables were retained in all models that included s-ferritin (Table 5 ). The s-ferritin level was identified as a significant risk factor for LVH after HCT in both the univariable and multivariable logistic analyses (Table 5 ). However, we could not identify a significant effect of chronic GVHD on cardiac function or LVH after HCT.
DISCUSSION
Our study shows that myeloablative conditioning, in particular regimens that included high-dose TBI, adversely affected cardiac function even in the chronic phase of HCT. Unexpectedly, we could not establish a significant correlation between chronic GVHD and cardiac function. Notably, the s-ferritin level was identified as an independent risk factor for LVH after HCT.
A long-term follow-up study of cardiac function after HCT in children showed similar results, with a report that TBI was a risk factor for cardiac dysfunction. 13 In contrast, Auner et al. 7 reported that high-dose TBI combined with high-dose CY was not associated with a significant decrease in cardiac function. However, these investigators evaluated cardiac function after a relatively short-term follow-up period, with a median of just 5 months. Radiotherapy-induced late cardiotoxicity has often been described in patients with Hodgkin's lymphoma who received mediastinal radiotherapy.
14-17 Pathological examination of radiotherapy-induced myocarditis showed diffuse interstitial fibrosis and microcirculatory damage, leading to capillary obstruction and extensive fibrosis, 14 with the potential to cause LV systolic and diastolic dysfunction. 16, 17 In addition, CY-containing regimens without high-dose TBI significantly reduced LV diastolic function but not systolic function. Therefore, our results suggest that chronic LV systolic dysfunction after HCT might largely reflect a late, toxic effect of TBI.
There were differences in the pre-transplant LVEF and E/A in the three groups of conditioning regimens in our study-the LVEF and E/A before HCT in the two myeloablative conditioning groups were better than those in the RIC group. We thought that the results likely indicated that the patients receiving myeloablative conditioning regimens were younger and/or had fewer cardiac complications than the RIC patients.
Our data demonstrated that the s-ferritin level pre-HCT, rather than age or a history of HT, was significantly associated with development of LVH after HCT. A high s-ferritin level has been thought to reflect iron overload. 18 Although transfusion-related iron overload was reported to be causally associated with LVH, 19 the causal association between the s-ferritin level and LVH is still unclear. However, release of ferritin could be induced by IL-1 beta or TNF-alpha. 20 Thus, the relationship between the s-ferritin level and LVH might indicate that IL-1 beta or TNF-alpha was involved in the pathogenesis of myocyte hypertrophy. Further study will be required to elucidate the precise mechanism of development of LVH after HCT.
In our study, the presence of chronic GVHD did not appear to have any significant impact on cardiac function after HCT. There are some reports of cardiac dysfunction during GVHD but these are just case series. [21] [22] [23] [24] However, a larger, retrospective cohort study showed no statistically significant difference in the incidence of congestive heart failure among patients with acute GVHD, those with a history of chronic GVHD and Abbreviations: A ¼ mitral late diastolic velocity; anthracyclines ¼ cumulative dose of anthracyclines; b ¼ regression coefficient; b 0 ¼ standardized regression; Chronic GVHD ¼ the presence of chronic GVHD within 1 year of HCT; CI ¼ confidence interval; E ¼ peak early mitral inflow velocity; E/A ¼ the ratio of peak mitral E to A filling velocities; HCT ¼ allogeneic hematopoietic cell transplantation; HT ¼ a history of hypertension within 1 year of HCT; LVEF ¼ left-ventricular ejection fraction; RIC ¼ reduced intensity conditioning; s-ferritin ¼ serum ferritin level before HCT. High-dose TBI-based (vs RIC) and high-dose BU-based (vs RIC) regimens achieved significance in all models. Po0.05 is statistically significant. Bold type indicates data that achieved statistical significance.
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This study was limited by its retrospective, nonrandomized design and small study population. The incidence of cardiac dysfunction might be underestimated because of survivor bias. In addition, some patients were excluded from analysis because of a change in hospital or lack of echocardiographic data pre-HCT. A further limitation was related to the assessment of cardiac diastolic dysfunction. E/A, used as a surrogate marker of cardiac diastolic function in our study, can be influenced by multiple factors that include heart rate, 26, 27 loading conditions 26, 28 and/or valvular regurgitation. 29 However, none of our patients had features of heart failure, such as tachycardia, dyspnea or edema. In addition, no patient had severe mitral regurgitation or stenosis.
In conclusion, our results suggest that intensive conditioning, especially regimens that involved high-dose TBI for HCT, had a significant negative effect on chronic cardiac function; a high level of s-ferritin was also found to be a crucial risk factor for LVH in the chronic phase after HCT. Long-term survivors who received an intensive conditioning regimen should therefore have their cardiac function carefully monitored, as well as the function of other organs. In the future, a larger, adequately powered, prospective study of adult HCT patients will be required to confirm our observations.
